Integral Diagnostics Ltd (ASX:IDX) is a provider of medical imaging services across Australia and New Zealand. Its clinics offer diagnostic imaging modalities such as X-ray, ultrasound, CT, MRI and PET, and the group also operates a teleradiology platform called IDXt. IDX describes its model as a medical Leadership approach, employing radiologists and imaging specialists to support patient care, service and access. The company merged with Capitol Health in December 2024, significantly increasing its network size. Jason Martinez is Managing Director and CEO.

On 2 October 2026, IDX shares were trading at $2.15, up 0.94%. The company reports in Australian dollars, and its financial year ends on 30 June. Its most recent full-year results, released in August, covered the first full year including the Capitol business.

Recent Developments

On 25 August 2026, IDX announced its results for the year ended 30 June 2026, consistent with the unaudited preliminary results released on 10 August 2026. Key figures include:

  • Revenue and other income rose 25.6% to $788.7 million.
  • Operating EBITDA increased 30.3% to $164.8 million, with the Margin up 80 basis points to 20.9%.
  • Operating NPAT rose 50.1% to $47.4 million.
  • Statutory NPAT was $22.0 million, including $25.4 million of transaction, integration, restructuring and other costs, net of tax.
  • Operating free Cash Flow increased 30.7% to $106.4 million, with conversion of 82.0%.
  • Net Debt to operating EBITDA fell to 2.3 times from 2.6 times.
  • Operating diluted EPS rose 23.6% to 12.6 cents.
  • A fully franked final Dividend of 6.0 cents per share was declared, up 50.0%, bringing FY26 dividends to 9.3 cents per share.

Mr Martinez said IDX delivered solid Revenue growth, improved margins and disciplined execution, in line with guidance. Revenue growth was driven by patient volumes, Medicare indexation and a favourable mix, at 7.0% on a constant currency basis excluding closed or sold sites. Organic revenue in Australia grew 7.4%, with the legacy IDX Business up 8.9%, supported by MRI deregulation and the National Lung Cancer Screening Program, and the legacy Capitol business up 5.4%. Average fees per exam in Australia rose 6.5%, while organic revenue in New Zealand grew 2.1%.

The company said the Merger integration is largely complete, with annual ongoing synergies of more than $14.0 million, compared with at least $10.0 million expected at the time of the merger. At 30 June 2026, IDX held $51.3 million in cash and $117.0 million of undrawn committed facilities. The weighted average Interest Rate on its core debt fell to 5.36% from 6.24%. FY27 replacement and growth Capital Expenditure is expected to be $50 million to $60 million, and the company is targeting EBITDA margin improvement above 21.0%.

Operating EBITA increased 38.8% to $97.1 million, with the margin rising to 12.3% from 11.1%. Net debt, excluding Lease liabilities, was $298.9 million, broadly unchanged from $298.0 million, and the net debt to Equity ratio was 43.9%. About 51.2% of gross debt was hedged from late December at an interest rate the company described as favourable compared with the current BBSY rate. FY26 capital expenditure totalled $49.8 million, including $21.0 million on growth initiatives such as brownfield and greenfield sites. IDX said its group procurement function delivered savings above initial synergy projections and that teleradiology scale increased with contributions from Capitol radiologists. Mr Martinez said the company also maintained high patient satisfaction while supporting more patients and referrers across Australia and New Zealand.

Sector Context

Diagnostic imaging is a core part of healthcare, supporting diagnosis and treatment decisions across a wide range of conditions. Demand is driven by an ageing population, increasing use of advanced imaging such as MRI and PET, and government screening programs. In Australia, Medicare funding and indexation are key revenue drivers for imaging providers.

The sector faces challenges including radiologist shortages, rising labour and equipment costs, and the need for ongoing Investment in technology. Teleradiology and artificial intelligence are being used to improve productivity and extend reporting capacity. Industry consolidation has created larger groups with greater scale, but integrating acquisitions requires careful management of systems and staff.

In Australia, the deregulation of MRI licences and the National Lung Cancer Screening Program, which began in July 2025, have expanded the pool of eligible scans for imaging providers. Medicare indexation of 2.4% on most diagnostic imaging services from 1 July 2025 also supported fees. In New Zealand, imaging providers operate in a mix of public and private funding arrangements, and growth can depend on referral patterns and health system capacity.

Risks and Uncertainties

IDX's revenue depends heavily on Medicare funding, and changes to indexation or rebate policies could affect earnings. The legacy Capitol business grew more slowly than the legacy IDX business, reflecting lower GP attendances and referrals. Radiologist and staff availability can constrain capacity and raise costs. Net debt remains material at $298.9 million, and Leverage targets depend on Earnings growth. Statutory profit was significantly lower than operating profit due to integration and other costs.

IDX's growth in Australia trailed overall Medicare imaging growth, at 7.4% compared with 9.4%, which suggests competition for referrals remains a factor. Equipment costs for high-end modalities such as MRI and PET are significant, and the company plans to spend $50 million to $60 million on capex in FY27.

Catalysts Investors Can Watch

Investors may watch for progress toward the EBITDA margin target above 21.0%, further de-gearing, and growth in higher-value modalities and teleradiology. Updates on Medicare indexation, network expansion and the half-year result in early 2027 will also be relevant.

The company's stated FY27 priorities include core growth and optimisation, disciplined network expansion, people and culture, and transformation and innovation, so updates on each of these areas may help investors assess progress. Comments on interest costs and hedging may also be relevant given the company's de-gearing goal.

Final Thoughts

IDX's FY26 result showed revenue, earnings and dividend growth, with merger synergies ahead of expectations and lower leverage. Margin improvement and continued de-gearing are likely to remain key areas to follow.